Search research articles
Contact Us
Filters
Showing results (231-240 of 310) with videos related to
Page
of 31
Sort By:
Blut
|
February 1, 1988
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha
R Hehlmann, B Anger, D Messerer, et al.
Bone Marrow Transplantation
|
May 1, 1996
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia
H Heimpel, N C Allan, M Baccarani, et al.
Leukemia
|
November 9, 2000
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
S Saussele, A Weisser, M C Müller, et al.
Blood
|
July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
British Journal of Haematology
|
September 30, 1998
BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha
A Reiter, S B Marley, A Hochhaus, et al.
Journal of the National Cancer Institute
|
June 13, 1998
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
J Hasford, M Pfirrmann, R Hehlmann, et al.
Pathology, Research and Practice
|
November 1, 1985
Immunopathology of AIDS (acquired immune deficiency syndrome) observations in 75 patients with pre-AIDS and AIDS
G R Krueger, J K Otten, M Ortmann, et al.
Annals of Hematology
|
August 1, 1993
Interferon in chronic myeloid leukemia. A workshop report
M Griesshammer, R Hehlmann, A Hochhaus, et al.
Onkologie
|
July 7, 2001
Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial
G. Hartung, R. Hofheinz, D. Buchheidt, et al.
Journal of Interferon Research
|
August 1, 1994
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia
P Von Wussow, R Hehlmann, T Hochhaus, et al.
Page
of 31
Search research articles
Search
Showing results (231-240 of 310) with videos related to
Sort By:
Page
of 31
Blut
|
February 1, 1988
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha
R Hehlmann, B Anger, D Messerer, et al.
Bone Marrow Transplantation
|
May 1, 1996
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia
H Heimpel, N C Allan, M Baccarani, et al.
Leukemia
|
November 9, 2000
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes
S Saussele, A Weisser, M C Müller, et al.
Blood
|
July 15, 1993
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
R Hehlmann, H Heimpel, J Hasford, et al.
British Journal of Haematology
|
September 30, 1998
BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha
A Reiter, S B Marley, A Hochhaus, et al.
Journal of the National Cancer Institute
|
June 13, 1998
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
J Hasford, M Pfirrmann, R Hehlmann, et al.
Pathology, Research and Practice
|
November 1, 1985
Immunopathology of AIDS (acquired immune deficiency syndrome) observations in 75 patients with pre-AIDS and AIDS
G R Krueger, J K Otten, M Ortmann, et al.
Annals of Hematology
|
August 1, 1993
Interferon in chronic myeloid leukemia. A workshop report
M Griesshammer, R Hehlmann, A Hochhaus, et al.
Onkologie
|
July 7, 2001
Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial
G. Hartung, R. Hofheinz, D. Buchheidt, et al.
Journal of Interferon Research
|
August 1, 1994
Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia
P Von Wussow, R Hehlmann, T Hochhaus, et al.
Page
of 31